Investor Relations

Stock Quote (NASDAQ: DNDN)
Price:
8.62
Change:
- 0.22
Volume:
4,115,000
4:03 PM ET on May 16, 2012
Delayed at least 20 minutes.
Provided by eSignal.
Stock price graph
     

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

View all »   RSSRecent Releases

May 16, 2012
Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting

May 7, 2012
Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth

Apr 9, 2012
Dendreon to Host Conference Call on May 7 to Announce First Quarter Financial Results and Webcast Presentations at Upcoming Conferences



View all »Webcasts

May 16, 2012 at 5:00 PM PT
Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas

May 9, 2012 at 11:15 AM CT
Baird's 2012 Growth Stock Conference



View all »Presentations

MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Investor Relations
206-455-2220
ir@dendreon.com

Media
206-829-1622
media@dendreon.com